Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 236,386,858 papers from all fields of science
Search
Sign In
Create Free Account
Vandetanib
An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
7 relations
Narrower (2)
Caprelsa
ZD 6474
NCIt Antineoplastic Agent Terminology
Receptor Tyrosine Kinase Inhibition
Vandetanib 300 MG Oral Tablet [Caprelsa]
docetaxel/ZD6474
Broader (1)
Zactima
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
RET-rearranged lung cancers: Immunophenotype and response to immunotherapy.
J. Sabari
,
M. Offin
,
+15 authors
A. Drilon
2018
Corpus ID: 81717359
9034Background: In patients with RET-rearranged lung cancers, multikinase inhibitors (e.g. cabozantinib and vandetanib) and…
Expand
2018
2018
Erythrocytosis caused by Vandetanib treatment in metastatic medullary thyroid carcinoma: the first case report
Mariana Costache Outas
,
A. Colita
Endocrine Abstracts
2018
Corpus ID: 81753469
Vandetanib is selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2…
Expand
2013
2013
Angiogenesis and Lung Cancer
S. Vázquez
,
U. Anido
,
+5 authors
L. Aparicio
2013
Corpus ID: 49554699
Tumors acquire blood vessels by co-option of neighboring vessels from sprouting or intus‐ suscepted microvascular growth and by…
Expand
Review
2012
Review
2012
Vandetanib,a new drug for the treatment of medullary thyroid cancer
Du Hai-zhou
2012
Corpus ID: 75578403
Vandetanib is an orally active antagonist of vascular endothelial growth factor(VEGF) receptor-2(VEGFR-2),epidermal growth factor…
Expand
2011
2011
Synthesis of anticancer drug vandetanib
Liu Yu
,
Xia Chao
,
Liu Yuan
2011
Corpus ID: 78672875
目的 合成凡德他尼(vandetanib)并改进其合成工艺.方法 以N-Boc-4-哌啶甲醇为起始原料,经磺化、缩合、N…
Expand
2010
2010
A phase I study of two different schedules of nab-paclitaxel (Nab-p) with ascending doses of vandetanib (V) in patients (pts) with advanced solid tumors.
A. El-Khoueiry
,
S. Iqbal
,
+7 authors
A. Garcia
2010
Corpus ID: 74600790
3059 Background: Nab-p is an albumin bound paclitaxel. V is a potent inhibitor of VEGFR 2 and EGFR. Preclinical data reveal…
Expand
2010
2010
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) in previously treated metastatic colorectal cancer (mCRC).
J. Meyerhardt
,
D. Schrag
,
+7 authors
T. Abrams
2010
Corpus ID: 79187287
e14055 Background: Given limits of individual targeted therapies in the treatment of mCRC, combining agents is increasingly…
Expand
2008
2008
A randomized open-label phase I study to assess the effect of vandetanib on vascular permeability in patients with advanced colorectal cancer and liver metastases
K. Mross
,
A. Frost
,
+7 authors
R. Fischer
2008
Corpus ID: 68154398
4113 Background: Vandetanib is a once-daily oral inhibitor of VEGFR-2, VEGFR-3, EGFR and RET tyrosine kinases. Dynamic contrast…
Expand
2007
2007
Vandetanib with mFOLFOX6 in advanced colorectal adenocarcinoma: An open-label, multicenter phase I study
M. Michael
,
N. Tebbutt
,
P. Gibbs
,
Robert P. Smith
,
A. Godwood
,
S. Oliver
2007
Corpus ID: 57151806
4095 Background: Vandetanib (ZD6474) is a once-daily oral anticancer agent that selectively inhibits VEGFR- dependent tumor…
Expand
2007
2007
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: an open-label, multicenter Phase I study
M. Saunders
,
E. Cutsem
,
+4 authors
S. Oliver
2007
Corpus ID: 74037844
4085 Background: Vandetanib (ZD6474) is a once-daily oral agent in Phase III development that selectively targets key signaling…
Expand